Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
(Nasdaq: BNVI) today announced that the FDA has reviewed the company’s
manufacturing and control process descriptions (CMC), and has provided
guidance on how Bionovo can move forward with the development of Menerba
(formerly named MF101) for menopausal hot flashes.
“We have concluded three CMC discussions with the FDA, and are moving to
address the Agency’s recommendations for further development of Menerba. The
recommendations with respect to the analytical characterization were made by
the Pre-Marketing division of the Agency, in order to ensure continuous drug
consistency. There are some areas of the drug development process requiring
further discussion on how to best implement the Agency’s Guidance for Industry
for Botanical Drug Products. Bionovo will be moving with all possible
diligence to reach agreement on these areas with the FDA. We will start
manufacturing the clinical material using the commercial process immediately.
During these discussions no concerns were expressed about either the safety
nor the efficacy of Menerba,” said Dr.
Bionovo completed a multicenter Phase 2, double-blind, placebo-controlled
randomized clinical trial evaluating Menerba for the treatment of hot flashes
in 217 healthy post-menopausal women enrolled at 6 clinical sites in the U.S.
The principal investigator of the trial was Dr.
significant reduction in the number of hot flashes after 12 weeks of treatment
(-62%, p=0.05) and had a statistically significant reduction in nighttime
awakenings from hot flashes (-67%, p=0.05). There was no difference in uterine
bleeding between treatment groups and placebo, and no uterine abnormalities
were observed during the study. The only side effect observed was mild loose
stools (12% in treatment group vs. 3% in the placebo group). To date, no
significant toxicities have been observed in any of the animal studies with
doses ranging from 2000 mg/kg/day in dogs to 16,000 mg/kg/day in rodents.
“The positive results of Menerba to date are very encouraging. Our
discussions with the FDA clinical staff, our Scientific Advisory Board, our
clinical investigators, and our reception at the many scientific conferences
at which we have presented — all have served to strengthen our confidence
that Bionovo’s Menerba will be able to provide menopausal women with a safe
and efficacious alternative to the existing drugs on the market. This is
particularly important because all current drugs for hot flashes carry six
black box warnings by the FDA for potentially serious adverse events. As a
next step, we have plans to meet with the clinical review team at the FDA to
reach an agreement on the clinical path forward,” said Dr.
M.D., Bionovo’s President and Chief Medical Officer.
“Menerba provides a true paradigm shift in the treatment of menopausal hot
flashes. The novel mechanism of action, the exciting preclinical and clinical
safety, and the early efficacy are encouraging. I believe swift development is
warranted so we can provide women with an alternative to hormone therapy,”
North American Menopause Society and Menerba’s Principal Clinical
The Company expects to initiate clinical trials by the second quarter of
2009 subject to FDA review.
Menerba is an estrogen receptor (ER) beta selective drug developed as an
alternative to postmenopausal hormone products currently on the market, which
are both ER beta and ER alpha agonists that have been shown to increase the
risk for breast and uterine cancers. It has been shown that the increased risk
of breast and uterine cancers is associated with ER alpha activation and that
ER beta blocks the growth promoting effects on breast cancer cells. Bionovo
recognized the opportunity to commercialize a product that would be equally
effective, with an improved safety profile compared to traditional hormone
therapy. The clinical trial results have been evaluated by an independent Data
and Safety Monitoring Board and the drug candidate has passed through a
standard two-phase examination for safety.
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women’s health and cancer,
markets with significant unmet needs and billions in potential annual revenue.
The company applies its expertise in the biology of menopause and cancer to
design new drugs derived from botanical sources which have novel mechanisms of
action. Based on the results of early and mid-stage clinical trials, Bionovo
believes they have discovered new classes of drug candidates within their rich
pipeline with the potential to be leaders in their markets. Bionovo is
Market under the symbol, “BNVI”. For more information about Bionovo and its
programs, visit http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the
business of Bionovo, Inc. that can be identified by the use of forward-looking
terminology such as “believes,” “expects,” or similar expressions. Such
forward-looking statements involve known and unknown risks and uncertainties,
including uncertainties relating to product development, efficacy and safety,
regulatory actions or delays, the ability to obtain or maintain patent or
other proprietary intellectual property protection, market acceptance,
physician acceptance, third party reimbursement, future capital requirements,
competition in general and other factors that may cause actual results to be
materially different from those described herein as anticipated, believed,
estimated or expected. Certain of these risks and uncertainties are or will be
described in greater detail in our filings with the Securities and Exchange
Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under
no obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information, future
events or otherwise.
SOURCE Bionovo, Inc.